Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.
A retrospective analysis of data collected from over 14,000 childhood cancer survivors has found an increased risk of recurrent stroke decades after their first stroke. This risk is especially high in those who had been treated with cranial radiation, the study published in Neurology states.
The 14,358 survivors were less than 21 years of age at diagnosis and had survived at least 5 years subsequent to diagnosis. Enrolled in The Childhood Cancer Survivor Study, these patients, diagnosed primarily between 1970 and 1986, were prospectively followed till 1994. For the current study, the authors evaluated a cohort of 443 survivors who had suffered a stroke, 74% (329) of whom responded.
Two hundred and seventy one of the 329 confirmed a first stroke at a median age of 19 years (range 0-53 years) and 70 had a second stroke at a median age of 32 years (range 1-56 years). Cranial radiation therapy (≥50 Gy), hypertension, and an advanced age at first stroke were all identified by the authors as predictors of recurrent stroke. The 10-year cumulative incidence of late recurrent stroke was 21% (95% confidence interval (CI), 16%-27%) overall, and 33% (95% CI, 21%-44%) for those treated with ≥50 Gy of radiation, the authors found.
“We are at a point where more children are surviving cancer because of life-saving interventions. Now, we are facing long-term problems associated with these interventions,” said Sabine Mueller, MD, PhD, director of the UCSF Pediatric Brain Tumor Center in UCSF Benioff Children’s Hospital San Francisco and coauthor of the study.
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More